v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Current Assets    
Cash and cash equivalents $ 6,849 $ 14,565
Short-term investments 292 0
Accounts receivable (net of allowance for doubtful accounts of $108 in 2026 and $97 in 2025) 12,564 11,775
Inventories (excludes inventories of $6,381 in 2026 and $5,681 in 2025 classified in Other assets - see Note 6) 6,207 6,658
Other current assets 10,767 10,518
Total current assets 36,679 43,516
Investments 1,222 956
Property, Plant and Equipment, at cost, net of accumulated depreciation of $22,729 in 2026 and $21,914 in 2025 25,737 25,316
Goodwill 21,582 21,579
Other Intangibles, Net 24,978 26,681
Other Assets 19,604 18,818
Total Assets 129,802 136,866
Current Liabilities    
Loans payable and current portion of long-term debt 2,825 2,589
Trade accounts payable 3,827 4,404
Accrued and other current liabilities 14,725 14,468
Income taxes payable 4,224 4,726
Dividends payable 2,130 2,140
Total current liabilities 27,731 28,327
Long-Term Debt 51,081 46,750
Deferred Income Taxes 1,433 1,439
Other Noncurrent Liabilities 7,573 7,688
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2026 and 2025 1,788 1,788
Other paid-in capital 44,950 45,029
Retained earnings 63,269 73,075
Accumulated other comprehensive loss (3,942) (4,287)
Stockholders' equity before deduction for treasury stock 106,065 115,605
Less treasury stock, at cost: 1,108,460,187 shares in 2026 and 1,102,476,756 shares in 2025 64,132 62,999
Total Merck & Co., Inc. stockholders’ equity 41,933 52,606
Noncontrolling Interests 51 56
Total equity 41,984 52,662
Liabilities and Equity $ 129,802 $ 136,866